Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Other Accumulated Expenses (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Other Accumulated Expenses readings, the most recent being $75.2 million for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 52.57% to $75.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $75.2 million, a 52.57% increase, with the full-year FY2025 number at $75.2 million, up 52.57% from a year prior.
  • Other Accumulated Expenses hit $75.2 million in Q4 2025 for Tandem Diabetes Care, down from $96.9 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $100.0 million in Q2 2025 to a low of $18.3 million in Q2 2021.
  • Median Other Accumulated Expenses over the past 5 years was $30.2 million (2023), compared with a mean of $41.3 million.
  • Biggest five-year swings in Other Accumulated Expenses: dropped 2.94% in 2023 and later soared 202.63% in 2025.
  • Tandem Diabetes Care's Other Accumulated Expenses stood at $23.4 million in 2021, then increased by 25.38% to $29.3 million in 2022, then decreased by 2.94% to $28.5 million in 2023, then skyrocketed by 73.26% to $49.3 million in 2024, then skyrocketed by 52.57% to $75.2 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $75.2 million (Q4 2025), $96.9 million (Q3 2025), and $100.0 million (Q2 2025) per Business Quant data.